4.6 Review

Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol

期刊

BMJ OPEN
卷 11, 期 3, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2020-044765

关键词

immunology; internal medicine; rheumatology

资金

  1. SRUK (Scleroderma and Raynaud UK)
  2. WSF (World Scleroderma Foundation) [UHUHR1]
  3. National Institutes of Health/NIAMS grant [K24 AR063120]
  4. NIH/NIAMS T32 grant [AR007080]
  5. French network of the University Hospitals HUGO (Hopitaux Universitaire du Grand Ouest) [AAP JCM2020]
  6. 2020 CORECT grant from the Rennes University Hospital (France)

向作者/读者索取更多资源

Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of systemic sclerosis, yet lacks focus in clinical studies. The objective of this scoping review is to identify the outcome measures used to assess lcSSc.
Introduction Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of systemic sclerosis. Despite this, lcSSc is not the major focus of clinical studies. The lack of interventional studies in lcSSc is due, in part, to a paucity of relevant outcome measures to effectively evaluate this subset. A combined response index dedicated to lcSSc would facilitate development of well-designed trials and approval of new drugs. The objective of this scoping review is to perform a broad and comprehensive identification of the outcome measures (core set items) within relevant domains, which have been used so far to assess lcSSc. Methods and analysis The planned scoping review will be based on the approach proposed by Arksey et al and further developed by Levac et al. Development and reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Extension for Scoping Reviews checklist and guidelines. The development of the search strategy was guided by the concepts of domains and outcomes based on the Outcome Measures in Rheumatology approach and by the different names and definitions of SSc, with a specific emphasis on their occurrence in clinical trial studies. Two databases will be searched: MEDLINE and Embase. Studies in English, published from the year 1988 onwards, will be included, since 1988 corresponds to the publication of LeRoy's first consensus definition of lcSSc. Data will be extracted and analysed using a standardised charting tool. Ethics and dissemination No ethical approval is required for this study. The results will be submitted to an international peer-reviewed journal and scientific conferences, informing the discussion on which items should be included in a combined response index dedicated to lcSSc (the CRISTAL project: Combined Response Index for Scleroderma Trial Assessing lcSSc).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据